Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses factors to consider when selecting patients with acute lymphoblastic leukemia (ALL) for stem cell transplantation (SCT), including cytogenetic risk and measurable residual disease (MRD) status. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.